NO976064D0 - Somatostatin peptider - Google Patents

Somatostatin peptider

Info

Publication number
NO976064D0
NO976064D0 NO976064A NO976064A NO976064D0 NO 976064 D0 NO976064 D0 NO 976064D0 NO 976064 A NO976064 A NO 976064A NO 976064 A NO976064 A NO 976064A NO 976064 D0 NO976064 D0 NO 976064D0
Authority
NO
Norway
Prior art keywords
residue
ala
amino acid
lys
somatostain
Prior art date
Application number
NO976064A
Other languages
English (en)
Other versions
NO317867B1 (no
NO976064L (no
Inventor
Rainer Albert
Wilfried Bauer
Christian Bruns
Nagarajan Chandramouli
Ian Lewis
Gisbert Weckbecker
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26307298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO976064(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9513224.7A external-priority patent/GB9513224D0/en
Priority claimed from GBGB9600429.6A external-priority patent/GB9600429D0/en
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO976064D0 publication Critical patent/NO976064D0/no
Publication of NO976064L publication Critical patent/NO976064L/no
Publication of NO317867B1 publication Critical patent/NO317867B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
NO19976064A 1995-06-29 1997-12-23 Sykliske somatostatin heksapeptider, farmasoytiske sammensetninger omfattende slike, og anvendelse av slike heksapeptider for fremstilling av farmasoytiske sammensetninger. NO317867B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9513224.7A GB9513224D0 (en) 1995-06-29 1995-06-29 Organic compounds
GBGB9600429.6A GB9600429D0 (en) 1996-01-10 1996-01-10 Organic compounds
PCT/EP1996/002840 WO1997001579A2 (en) 1995-06-29 1996-06-28 Somatostatin peptides

Publications (3)

Publication Number Publication Date
NO976064D0 true NO976064D0 (no) 1997-12-23
NO976064L NO976064L (no) 1998-02-16
NO317867B1 NO317867B1 (no) 2004-12-27

Family

ID=26307298

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19976064A NO317867B1 (no) 1995-06-29 1997-12-23 Sykliske somatostatin heksapeptider, farmasoytiske sammensetninger omfattende slike, og anvendelse av slike heksapeptider for fremstilling av farmasoytiske sammensetninger.

Country Status (24)

Country Link
US (1) US6225284B1 (no)
EP (1) EP0835263B9 (no)
JP (2) JP3445796B2 (no)
KR (1) KR100454664B1 (no)
CN (1) CN1156492C (no)
AT (1) ATE210152T1 (no)
AU (1) AU714447B2 (no)
BR (1) BR9609335B8 (no)
CA (1) CA2222524C (no)
CZ (1) CZ297381B6 (no)
DE (1) DE69617687T2 (no)
DK (1) DK0835263T3 (no)
ES (1) ES2169251T3 (no)
HU (1) HU228984B1 (no)
IL (1) IL122243A (no)
MY (1) MY147327A (no)
NO (1) NO317867B1 (no)
NZ (1) NZ313147A (no)
PL (1) PL184947B1 (no)
PT (1) PT835263E (no)
SK (1) SK284087B6 (no)
TR (1) TR199701718T1 (no)
TW (1) TW491854B (no)
WO (1) WO1997001579A2 (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238340B1 (en) * 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
JPH10251296A (ja) * 1997-03-06 1998-09-22 American Cyanamid Co ソマトスタチン拮抗薬として有用なペプチド
WO1998051331A1 (en) 1997-05-13 1998-11-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Somatostatin and somatostatin agonists for decreasing body weight
US7026289B2 (en) 1997-05-13 2006-04-11 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Method and compositions for treating hyperlipidemia and other conditions
US6004928A (en) * 1997-05-13 1999-12-21 Biomeasure, Incorporated Method of treating hyperlipidemia
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
SE9802080D0 (sv) * 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6358491B1 (en) 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
EP1233776A4 (en) * 1999-11-29 2003-05-07 Smithkline Beecham Corp CYCLIC UROTENSIN II ANALOGS
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US7122172B1 (en) 2000-03-08 2006-10-17 Gerhart Graupner Methods and compositions for targeted drug delivery
US7906103B2 (en) 2000-03-08 2011-03-15 Gerhard Graupner Methods and compositions for targeted drug delivery
JP3996897B2 (ja) 2001-06-08 2007-10-24 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス ソマトスタチン−ドーパミンキメラ類似体
US7189856B2 (en) * 2001-12-28 2007-03-13 Gideon Shapiro Non-peptide somatostatin receptor ligands
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
DE60335608D1 (de) * 2002-02-27 2011-02-17 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7122622B2 (en) 2002-04-16 2006-10-17 Biosynthema Inc. Peptide compounds having improved binding affinity to somatostatin receptors
EP1358890A1 (en) 2002-05-03 2003-11-05 BioSynthema, Inc Benzothienyl analogue of somatostatine, selective for certain somatostatin receptors
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
DE60336550D1 (de) * 2002-05-20 2011-05-12 Bristol Myers Squibb Co Inhibitoren des hepatitis-c-virus
JP4312711B2 (ja) 2002-05-20 2009-08-12 ブリストル−マイヤーズ スクイブ カンパニー ヘテロ環式スルホンアミドｃ型肝炎ウイルス阻害剤
AU2003301959A1 (en) 2002-05-20 2004-06-03 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
BR0316523A (pt) * 2002-11-25 2005-10-18 Attenuon Llc Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
GB0229020D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic compounds
KR101018491B1 (ko) * 2002-12-12 2011-03-03 노파르티스 아게 4-히드록시-프롤린 하부구조를 포함하는 펩티드의 합성 방법
GB0300095D0 (en) * 2003-01-03 2003-02-05 Novartis Ag Organic compounds
AU2004232314B2 (en) 2003-04-22 2007-11-22 Ipsen Pharma S.A.S. Peptide vectors
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
MXPA06003141A (es) 2003-09-22 2006-06-05 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c.
EP1522311A1 (fr) * 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
GB0326602D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP4682155B2 (ja) 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対して活性な大環状ペプチド
GB0428151D0 (en) 2004-12-22 2005-01-26 Novartis Ag Organic compounds
EP1717247A1 (en) * 2005-04-28 2006-11-02 Schering AG Cyclic peptides binding to the somatostatin receptor
WO2006114324A1 (en) * 2005-04-28 2006-11-02 Schering Ag Compounds comprising cyclized somatostatin receptor binding peptides
EP1941902A1 (en) * 2007-01-02 2008-07-09 Novartis AG Use of Somatostatin analogs in cluster headache
KR20100038417A (ko) * 2007-06-29 2010-04-14 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
JP5465666B2 (ja) * 2007-06-29 2014-04-09 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
RU2523416C2 (ru) 2007-11-28 2014-07-20 Новартис Аг Применение аналогов соматостатина при менингиоме
CN101883785B (zh) * 2007-12-03 2014-01-15 意大利法尔马科有限公司 新的非选择性生长抑素类似物
EP2067786A1 (en) 2007-12-07 2009-06-10 ITALFARMACO S.p.A. Novel non selective analogs of somatostatin
EP3590956A1 (en) 2008-06-12 2020-01-08 Ipsen Bioinnovation Limited Suppression of neuroendocrine diseases
JP5799397B2 (ja) 2008-06-12 2015-10-28 イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ 癌の抑制
DK2310042T3 (da) 2008-07-08 2013-03-04 Novartis Ag Anvendelse af pasireotid til behandling af endogen hyperinsulinæmisk hypoglykæmi
EP2213307A1 (en) 2009-02-03 2010-08-04 Novartis AG Injectable depot formulations
EP2172189A1 (en) 2008-10-01 2010-04-07 Novartis AG Pharmaceutical Compositions
EP2168983A1 (fr) 2008-09-30 2010-03-31 Ipsen Pharma Nouveaux composés octapeptidiques et leur utilisation thérapeutique
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
UY32325A (es) * 2008-12-19 2010-07-30 Gilead Sciences Inc Inhibidores de ns3 proteasa del vhc
EP2380596A1 (en) * 2010-04-20 2011-10-26 Technische Universität München Cyclopentapeptide derivatives and uses thereof
EP3233899B1 (en) 2014-12-19 2020-06-24 Auro Peptides LTD A process for the preparation of pasireotide
CN106432429A (zh) * 2016-10-24 2017-02-22 合肥国肽生物科技有限公司 一种帕西瑞肽的合成方法
RS64815B1 (sr) 2017-01-12 2023-12-29 Radiomedix Inc Lečenje ćelija kancera koje prekomerno eksprimiraju receptore za somatostatin primenom derivata oktreotida heliranih sa radioizotopima
US10596278B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3863008A (en) * 1973-06-11 1975-01-28 American Home Prod Somatostatin as stimulant of luteinizing hormone secretion
NZ195303A (en) * 1979-10-31 1984-10-19 Merck & Co Inc Cyclic hexapeptide somatostatin analogues,and pharmaceutical compositions
US4292972A (en) * 1980-07-09 1981-10-06 E. R. Squibb & Sons, Inc. Lyophilized hydrocolloio foam
US4505897A (en) * 1983-04-18 1985-03-19 The Administrators Of The Tulane Educational Fund Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith
US4612366A (en) 1985-06-17 1986-09-16 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
CA2012115C (en) * 1989-03-15 2001-07-03 Biomeasure, Inc. Iodinated somatostatins
CA2053250A1 (en) 1989-04-26 1990-10-27 David H. Coy Linear somatostatin analogs
US5716596A (en) * 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
CA2167281C (en) * 1993-07-15 2001-09-04 Richard T. Dean Radiolabeled somatostatin-derived peptides for imaging and therapeutic uses

Also Published As

Publication number Publication date
WO1997001579A3 (en) 1997-02-27
HU228984B1 (en) 2013-07-29
BR9609335B8 (pt) 2014-10-07
BR9609335B1 (pt) 2009-08-11
CZ297381B6 (cs) 2006-11-15
JPH11506108A (ja) 1999-06-02
JP3445796B2 (ja) 2003-09-08
CA2222524A1 (en) 1997-01-16
JP2003104998A (ja) 2003-04-09
IL122243A (en) 2005-09-25
SK177097A3 (en) 1998-08-05
NZ313147A (en) 1999-11-29
DE69617687D1 (de) 2002-01-17
NO317867B1 (no) 2004-12-27
WO1997001579A2 (en) 1997-01-16
NO976064L (no) 1998-02-16
US6225284B1 (en) 2001-05-01
DE69617687T2 (de) 2002-08-22
HUP9901455A2 (hu) 1999-09-28
KR19990028480A (ko) 1999-04-15
EP0835263B1 (en) 2001-12-05
KR100454664B1 (ko) 2005-09-12
SK284087B6 (sk) 2004-09-08
AU6515096A (en) 1997-01-30
CN1156492C (zh) 2004-07-07
CA2222524C (en) 2010-01-26
TW491854B (en) 2002-06-21
ATE210152T1 (de) 2001-12-15
EP0835263B9 (en) 2002-07-24
CN1189166A (zh) 1998-07-29
HUP9901455A3 (en) 2000-11-28
ES2169251T3 (es) 2002-07-01
IL122243A0 (en) 1998-04-05
AU714447B2 (en) 2000-01-06
TR199701718T1 (xx) 1998-05-21
PL184947B1 (pl) 2003-01-31
MY147327A (en) 2012-11-30
PT835263E (pt) 2002-04-29
DK0835263T3 (da) 2002-04-02
EP0835263A2 (en) 1998-04-15
BR9609335A (pt) 1999-05-25
CZ419697A3 (cs) 1998-05-13
PL323943A1 (en) 1998-04-27

Similar Documents

Publication Publication Date Title
ATE210152T1 (de) Somatostatinpeptide
ATE168719T1 (de) Osteogene peptide
DE69613137D1 (de) Zyklische peptidanaloga von somatostatin
KR840007569A (ko) Grf 유사체 펩티드의 제법
NZ222466A (en) Hexa to deca peptides capable of stimulating the proliferation of myelopoietic stem cells
ATE146188T1 (de) Substituierungsanaloge von magaininpeptiden
MX9709962A (es) Peptidos de somatostatina.
ES2051647A1 (es) Procedimiento para la preparacion de calcitonina de salmon.
ATE215558T1 (de) Biotinderivate
ECSP961798A (es) Peptidos de somatostatina
DK0946591T3 (da) Klonede glucagon-lignende peptid-2 receptorer
KR890701628A (ko) 단백질(성) 감미제의 제조
MX9205978A (es) Nuevas proteinas inhibidoras de trombina de garrapatas.
CO5090903A1 (es) Nuevos peptidos para ser usados en una terapia de tolerancia inducida para impedir las alteraciones autoinmunes, en particular, artritis reumatoidea
AR247473A1 (es) Una composicion que produce una respuesta lactogenica o crecimiento en ganado bovino, excluidas todas sus aplicaciones terapeuticas
AR004485A1 (es) Insulina de cadena sencilla con alta bioactividad
CO4340568A1 (es) Familia de peptidos con 51 aminoacidos en longitud, secuen- cias de definicion, la planta transgenica comprendida, el vector de expresion recombinante y el metodo para su pro- duccion.

Legal Events

Date Code Title Description
MK1K Patent expired